International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-2 doi: 10.5281/zenodo.15161668
Original Research Article
Comparative Analysis of Onlay versus Sublay Mesh Repair for Ventral Hernia: A Prospective Randomized Study
Published
April 2, 2025
Abstract

Background: Ventral hernia repair remains a common surgical procedure with ongoing debate regarding optimal mesh placement. This study aimed to compare the outcomes of onlay versus sublay mesh repair techniques for ventral hernia. Methods: A prospective randomized controlled trial was conducted at a tertiary care center between January 2023 and December 2024. Adult patients with ventral hernia (fascial defect size 3-15 cm) were randomized to either onlay (n=153) or sublay (n=155) mesh repair. Primary outcome was hernia recurrence at 12 months. Secondary outcomes included perioperative parameters, complications, patient-reported outcomes, and cost-effectiveness. Results: Baseline characteristics were comparable between groups. The sublay technique was associated with longer operative time (105.6±22.4 vs. 78.3±18.7 minutes, p<0.001) and greater blood loss (110 vs. 75 mL, p<0.001). However, seroma formation (7.7% vs. 24.2%, p<0.001), surgical site infection (5.8% vs. 13.7%, p=0.018), and hernia recurrence at 12 months (3.9% vs. 11.1%, p=0.017) were significantly lower in the sublay group. Multivariate analysis identified onlay repair as an independent predictor of recurrence (aOR=3.18, 95%CI:1.18-8.57, p=0.022). Patient satisfaction (8.2±1.3 vs. 7.4±1.6, p<0.001) and physical component summary of SF-36 (49.7±7.8 vs. 46.3±8.2, p<0.001) were significantly better in the sublay group. Conclusion: Despite requiring longer operative time and higher resource utilization, sublay mesh repair for ventral hernia demonstrates superior outcomes in terms of reduced seroma formation, surgical site infection, and recurrence rates, along with better patient satisfaction and quality of life. These findings support the preferential use of the sublay technique, particularly in high-risk patients.

Recommended Articles
Loading Image...
Volume-6, Issue-2
Citations
1281 Views
331 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved